T. Marbury

Posaconazole Pharmacokinetics, Safety, and Tolerability in Subjects With Varying Degrees of Chronic Renal Disease

Ronan Courtney, A Sansone, Winter J. Smith et al. · The Journal of Clinical Pharmacology · 2005 · 126 citations

Healthy Subjects, Dialysis Therapy, Clinical Mycology +20

1101 THE EFFECT OF RENAL IMPAIRMENT AND END STAGE RENAL DISEASE ON THE SINGLE-DOSE PHARMACOKINETICS OF PSI-7977

Melanie Cornpropst, Jill Denning, David Clemons et al. · Journal of Hepatology · 2012 · 72 citations

Hemodialysis, Urology, Renal Function +8

1186 SAFETY AND ANTIVIRAL ACTIVITY OF ABT-267, A NOVEL NS5A INHIBITOR, DURING 3-DAY MONOTHERAPY: FIRST STUDY IN HCV GENOTYPE-1 (GT1)-INFECTED TREATMENT-NAIVE SUBJECTS

Eric Lawitz, T. Marbury, Andrew Campbell et al. · Journal of Hepatology · 2012 · 24 citations

Antiviral Compound, Neurovirology, Immunology +10

2008 DOSE-RANGING, THREE-DAY MONOTHERAPY STUDY OF THE HCV NS3 PROTEASE INHIBITOR GS-9256

E.J. Lawitz, T. Marbury, Bradley Vince et al. · Journal of Hepatology · 2010 · 12 citations

Viral Hepatitis, Immunology, Antiviral Drug Development +9

1188 GS-6620, A LIVER-TARGETED NUCLEOTIDE PRODRUG, EXHIBITS ANTIVIRAL ACTIVITY AND FAVORABLE SAFETY PROFILE OVER 5 DAYS IN TREATMENT NAIVE CHRONIC HCV GENOTYPE 1 SUBJECTS

E.J. Lawitz, Jacqueline Hill, T. Marbury et al. · Journal of Hepatology · 2012 · 11 citations

Hepatology, Viral Hepatitis, Liver Physiology +9